In their cautious review, Shah and Shah \[[@b1]\] emphasized differences in regulations of personalized medicine (PM) among the three major authorities, the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Specific points regarding the differences, however, were not raised for the drugs they selected for discussion in their review. Given that the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) brings together the regulatory authorities and pharmaceutical industries of the USA, Europe and Japan, scientific and technical aspects of drug registration should be harmonized. To identify differences, if any, in regulations of PM, we investigated approvals of PM drugs in the three regions.

As a typical example of PM, we focused on PM \[[@b2]\] drugs whose pharmacogenomic biomaker is required on the label. We also studied ivacaftor and pertuzumab, which were omitted in the list \[[@b2]\] simply because they were approved after publication of the list. The US, European and Japanese approval data on these drugs were obtained from Drugs\@FDA (<http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/>), European public assessment reports (<http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125>) and the PMDA website (<http://www.info.pmda.go.jp/approvalSrch/PharmacySrchInit>?), respectively. We defined submission/approval delay as the difference between the date of submission/approval in the USA and that in the EU or in Japan.

Of 17 FDA-approved drugs and 18 indications whose biomarker is labelled as required, 13 drugs and 14 indications were approved in the EU, whereas 12 drugs and 12 indications were approved in Japan ([Table 1](#tbl1){ref-type="table"}). The median submission delay from the submission in the USA was 0 months in the EU and 21 months in Japan. The median approval delay from the approval in the USA was 6 months in the EU and 28 months in Japan.

###### 

US, EU and Japanese data on the approval of personalized medicine drugs whose pharmacogenomic biomarker is required on the label

  Generic name              US trade name   Indication         Biomarker       Submission date   Approval date   Submission delay (months)   Approval delay (months)                                                      
  ------------------------- --------------- ------------------ --------------- ----------------- --------------- --------------------------- ------------------------- ---------------- --------------- ----- ----- ----- ------
  **Arsenic trioxide**      Trisenox        APL                PML/RARα        March 2000        December 2000   June 2003                   September 2000            March2002        October2004     8     38    17    49
  **Cetuximab**             Erbitux         Colon cancer       EGFR, KRAS      August 2003       July 2003       January 2007                February 2004             June 2004        July 2008       --1   42    5     53
  **Crizotinib**            Xalkori         Lung cancer        ALK             March 2011        NA              March 2011                  August 2011               Unapproved       March 2012      ---   0     ---   7
  **Dasatinib**             Sprycel         CML/Ph1+ ALL       Ph1/BCR-ABL     December 2005     January 2006    August 2007                 June 2006                 November 2006    January 2009    0     20    5     31
  **Denileukin diftitox**   Ontak           Lymphoma           CD25            December 1997     NA              NA                          February 1999             Unapproved       Unapproved      ---   ---   ---   ---
  **Imatinib (1)**          Gleevec         CML                Ph1/BCR-ABL     February 2001     March 2001      April 2001                  May 2001                  November 2001    November 2001   0     2     6     6
  **Imatinib (2)**          Gleevec         MDS/MPD            PDGFR           December 2005     NA              NA                          October 2006              November 2006    Unapproved      ---   ---   1     ---
  **Ivacaftor**             Kalydeco        Cystic fibrosis    CFTR (G551D)    October 2011      October 2011    NA                          January 2012              July 2012        Unapproved      0     ---   6     ---
  **Lapatinib**             Tykerb          Breast cancer      Her2/neu        September 2006    October 2006    March 2007                  March 2007                June 2008        April 2009      1     7     15    25
  **Lenalidomide**          Revlimnid       Multiple myeloma   Chromosome 5q   April 2005        February 2006   June 2009                   December 2005             June 2007        August 2010     11    51    18    56
  **Maraviroc**             Selzentry       HIV                CCR5            December 2006     December 2006   October 2008                August 2007               September 2007   December 2008   0     22    1     17
  **Nilotinib**             Tasigna         CML/Ph1+ ALL       Ph1/BCR-ABL     September 2006    October 2006    June 2007                   October 2007              November 2007    January 2009    0     9     1     15
  **Panitumumab**           Vectibix        Colon cancer       EGFR, KRAS      December 2005     April 2006      June 2008                   September 2006            December 2007    April 2010      4     30    14    43
  **Pertuzumab**            Perjeta         Breast cancer      Her2/neu        December 2011     NA              NA                          June 2012                 Unapproved       Unapproved      ---   ---   ---   ---
  **Tositumomab**           Bexxar          Lymphoma           CD20 antigen    June 1999         NA              NA                          June 2003                 Unapproved       Unapproved      ---   ---   ---   ---
  **Trastuzumab**           Herceptin       Breast cancer      Her2/neu        May 1998          February 1999   January 2000                September 1998            August 2000      April 2001      9     21    23    30
  **Tretinoin**             Vesanoid        APL                PML/RARα        NA                NA              NA                          November 1995             December 1996    January 1995    ---   ---   13    --10
  **Vemurafenib**           Zelboraf        Melanoma           BRAF            April 2011        May 2011        NA                          August 2011               February 2012    Unapproved      0     ---   6     ---

Abbreviations are as follows: ALK, anaplastic lymphoma kinase; ALL, acute lymphoblastic leukaemia; APL, acute promyelocytic leukaemia; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CCR5, chemokine receptor type 5; CD, cluster of differentiation; CEL, chronic eosinophilic leukaemia; CFTR, cystic fibrosis transmembrane conductance regulator; CML, chronic myelogenous leukaemia; EGFR, epidermal growth factor receptor; GIST, malignant gastrointestinal stromal tumours; Her2/neu, human epidermal growth factor receptor 2; HES, hypereosinophilic syndrome; KRAS, Kirsten rat sarcoma 2 viral oncogene homolog; MDS/MPD, myelodysplastic syndrome/myeloproliferative diseases; NA, not available; PDGFR, platelet-derived growth factor receptor; Ph1/BCR-ABL, Philadelphia chromosome/breakpoint cluster region-Abelson tyrosine kinase; PML/RARα, promyelocytic leukemia/retinoic acid receptor alpha.

One would expect that labels would not differ significantly among countries, given that regulatory authorities evaluate the same scientific data. Both biological and nonbiological factors, however, can affect regulatory decisions. For example, a much lower incidence of cystic fibrosis \[[@b3]\] and melanoma \[[@b4]\] in Japan compared with the West could discourage the makers of ivacaftor and vemurafenib to file an application to the PMDA. Denileukin diftitox and tositumomab, which were approved for lymphoma by the FDA in 1999 and 2003, respectively, remain unavailable in both the EU and Japan, probably because better treatment modalities are available now.

The approval delay in Japan was observed in other therapeutic areas \[[@b5]\]. The present study shows that three-quarters of the approval delay consisted of delays in submission. The approval delay without submission delay in the EU indicates that the reviews took longer for the EMA than for the FDA. The cross-sectional design of our study makes causal inference of these delays difficult.

Our results show some similarities and differences in the approvals of PM drugs among the three regions of the ICH. Further studies are needed to investigate differences in postmarketing regulations of PM drugs, because such regulations are important for risk--benefit assessment of PM and are greatly affected by local factors, such as health polices, culture and financial settings.
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